{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:45:20Z","timestamp":1792403120641,"version":"4.4.0"},"reference-count":23,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Limited real-world evidence is available comparing the safety and effectiveness of apixaban and low-molecular-weight heparins (LMWHs) for preventing recurrent venous thromboembolism (VTE) in patients with active cancer receiving anticoagulation in an extended treatment setting. This study evaluated the risk of bleeding and recurrent VTE in patients with cancer-associated VTE who were prescribed apixaban or LMWH for \u22653 months.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A US commercial claims database was used to identify adult patients with VTE and active cancer who initiated apixaban or LMWH 30 days following the first VTE diagnosis and had \u22653 months of continuous enrollment and 3 months of primary anticoagulation treatment. Patients were followed from the day after the end of primary anticoagulation treatment until the earliest of: date of disenrollment, discontinuation of index anticoagulant, switch to another anticoagulant, or end of the study period. Inverse-probability treatment weighting (IPTW) was used to balance treatment cohorts. Incidence rates (IRs) for the outcomes were calculated per 100 person-years (PY). Cox proportional hazard models were used to evaluate the adjusted risk of recurrent VTE, major bleeding (MB), and clinically relevant nonmajor bleeding (CRNMB).\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 13,564 apixaban- and 2,808 LMWH-treated patients were analyzed. Post-IPTW, the treatment cohorts were balanced. Patients receiving apixaban had lower adjusted IRs for recurrent VTE (4.1 vs 9.6 per 100 PY), MB (6.3 vs 12.6), and CRNMB (26.1 vs 36.0) versus LMWH (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.0001 for all comparisons) during the follow-up period. Patients on apixaban had a lower adjusted risk of recurrent VTE (hazard ratio [HR], 0.42; 95% CI, 0.34\u20130.53), MB (HR, 0.50; 95% CI, 0.41\u20130.61), and CRNMB (HR, 0.76; 95% CI, 0.68\u20130.85) versus LMWH.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Extended anticoagulation treatment of \u22653 months with apixaban was associated with lower rates of recurrent VTE, MB, and CRNMB compared with LMWH in adults with cancer-associated VTE.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2024.7016","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T08:38:56Z","timestamp":1723797536000},"page":"397-403","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism"],"prefix":"10.6004","volume":"22","author":[{"given":"Alexander T.","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Hematological Medicine, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Dhamane","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Liu","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risho","family":"Singh","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Han","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stellhorn","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wang","sequence":"additional","affiliation":[{"name":"Cencora, Conshohocken, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Thromb Res","first-page":"490","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana AA","year":"2010","unstructured":"Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125:490\u2013493."},{"key":"B2","series-title":"Cancer Treat Rev","first-page":"102190","article-title":"Treatment of venous thromboembolism in cancer patients: the dark side of the moon","volume":"96","author":"Becattini C","year":"2021","unstructured":"Becattini C, Di Nisio M, Franco L,  Treatment of venous thromboembolism in cancer patients: the dark side of the moon. Cancer Treat Rev 2021;96:102190."},{"key":"B3","series-title":"PLoS Med","first-page":"e1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted F","year":"2012","unstructured":"Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012;9:e1001275."},{"key":"B4","series-title":"Arch Intern Med","first-page":"1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"Elting LS","year":"2004","unstructured":"Elting LS, Escalante CP, Cooksley C,  Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653\u20131661."},{"key":"B5","series-title":"Blood","first-page":"3484","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni P","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A,  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484\u20133488."},{"key":"B6","series-title":"Thromb Haemost","first-page":"57","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen AT","year":"2017","unstructured":"Cohen AT, Katholing A, Rietbrock S,  Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017;117:57\u201365."},{"key":"B7","series-title":"Chest","first-page":"315","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon C","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J,  Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315\u2013352."},{"key":"B8","series-title":"N Engl J Med","first-page":"615","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob GE","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P,  Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615\u2013624."},{"key":"B9","series-title":"J Clin Oncol","first-page":"2017","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young AM","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J,  Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017\u20132023."},{"key":"B10","series-title":"J Thromb Haemost","first-page":"411","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane RD II","year":"2020","unstructured":"McBane RD II, Wysokinski WE, Le-Rademacher JG,  Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020;18:411\u2013421."},{"key":"B11","series-title":"N Engl J Med","first-page":"1599","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli G","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G,  Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599\u20131607."},{"key":"B12","series-title":"Vascular","first-page":"745","article-title":"Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis","volume":"29","author":"Mokadem ME","year":"2021","unstructured":"Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular 2021;29:745\u2013750."},{"key":"B13","series-title":"J Clin Oncol","first-page":"3063","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update","volume":"41","author":"Key NS","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM,  Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update. J Clin Oncol 2023;41:3063\u20133071."},{"key":"B14","series-title":"Blood Adv","first-page":"927","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman GH","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C,  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927\u2013974."},{"key":"B15","series-title":"Eur Heart J","first-page":"4229","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS,  2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229\u20134361."},{"key":"B16","article-title":"Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease. Version 2","author":"Streiff MB","year":"2023","unstructured":"Streiff MB, Holmstrom B, Ashrani A,  Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease. Version 2.2023. Accessed December 11, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B17","series-title":"Thromb Haemost","first-page":"383","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis","volume":"121","author":"Cohen A","year":"2021","unstructured":"Cohen A, Keshishian A, Lee T,  Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2021;121:383\u2013395."},{"key":"B18","series-title":"N Engl J Med","first-page":"699","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli G","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A,  Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699\u2013708."},{"key":"B19","series-title":"Clin Pharmacol Ther","first-page":"133","article-title":"Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study","volume":"112","author":"Kang HR","year":"2022","unstructured":"Kang HR, Lo-Ciganic WH, DeRemer CE,  Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study. Clin Pharmacol Ther 2022;112:133\u2013145."},{"key":"B20","series-title":"JAMA","first-page":"1051","article-title":"Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism","volume":"327","author":"Pawar A","year":"2022","unstructured":"Pawar A, Gagne JJ, Gopalakrishnan C,  Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism. JAMA 2022;327:1051\u20131060."},{"key":"B21","series-title":"Thromb J","first-page":"21","article-title":"Current status of treatment of cancer-associated venous thromboembolism","volume":"19","author":"Xiong W","year":"2021","unstructured":"Xiong W. Current status of treatment of cancer-associated venous thromboembolism. Thromb J 2021;19:21."},{"key":"B22","article-title":"Healthcare map: the most complete view of the patient","author":"Komodo Health","unstructured":"Komodo Health. Healthcare map: the most complete view of the patient. Accessed June 12, 2023. Available at: https:\/\/www.komodohealth.com\/technology\/healthcare-map"},{"key":"B23","series-title":"Health Serv Res","first-page":"1839","article-title":"Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions","volume":"39","author":"Rector TS","year":"2004","unstructured":"Rector TS, Wickstrom SL, Shah M,  Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004;39:1839\u20131857."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/6\/article-p397.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/6\/article-p397.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/6\/article-p397.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T08:38:56Z","timestamp":1723797536000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/6\/article-p397.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7016","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}